• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOMET FRANCE S.A.R.L. REFOBACIN BC R 1X40 US; BONE CEMENT, ANTIBIOTIC

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOMET FRANCE S.A.R.L. REFOBACIN BC R 1X40 US; BONE CEMENT, ANTIBIOTIC Back to Search Results
Catalog Number 110034355
Device Problem Improper Chemical Reaction (2952)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Date 12/11/2019
Event Type  malfunction  
Manufacturer Narrative
(b)(4).The device was not returned to the manufacturer.Therefore it could not be analyzed.The investigation is in progress.Once the investigation has been completed, a follow-up mdr will be submitted.If any further information is found which would change or alter any conclusions or information, a supplemental will be filed accordingly.
 
Event Description
It was reported that bone cement texture was airy.This cement was used on multiple cases, this was account owned and they want a credit and one for one replacement for each type of cement.This issue concerns 89 products.No adverse event was reported.
 
Event Description
It was reported that bone cement was impossible to open texture was liked whipped butter "fluffy".This reports investigates cement paste consistency, however returned products showed packaging issues.This issue concerns 89 products.No adverse event was reported.
 
Manufacturer Narrative
(b)(4).This follow-up report is being submitted to relay additional information.The following section has been updated : b4, b5, d10, g4, g7, h1, h2, h6, h10.The product was returned and lab analysis was performed, showing a packaging difficult to open.An analysis on a retained sample from the same batch has been done and the cement is conform for cement paste consistency.The device manufacturing quality record indicate that the released product met all requirements to perform as intended.(b)(4) complaint, this one included, have been recorded over the batch 835aae2507 for cement paste consistency.With the available information, the exact root cause of the event could not be determined.If any further information is found which would change or alter any conclusions or information, a supplemental will be filed accordingly.Zimmer biomet will continue to monitor for trends.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
REFOBACIN BC R 1X40 US
Type of Device
BONE CEMENT, ANTIBIOTIC
Manufacturer (Section D)
BIOMET FRANCE S.A.R.L.
plateau de lautagne bp75
valence cedex 26903
FR  26903
MDR Report Key9537557
MDR Text Key219594050
Report Number3006946279-2019-00557
Device Sequence Number1
Product Code MBB
UDI-Device Identifier00880304990197
UDI-Public0880304990197
Combination Product (y/n)N
PMA/PMN Number
K151540
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional
Type of Report Initial,Followup
Report Date 06/26/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date07/31/2021
Device Catalogue Number110034355
Device Lot Number835AAE2507
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer12/27/2019
Was the Report Sent to FDA? No
Initial Date Manufacturer Received 12/13/2019
Initial Date FDA Received01/02/2020
Supplement Dates Manufacturer Received06/25/2020
Supplement Dates FDA Received06/26/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
-
-